Silexion Therapeutics

NASDAQ: SLXN ↗$0.39 USD~$18M (August 2026) MCAP

#KRAS-Driven Cancers #Pancreatic Cancer #Prostate Cancer #Glioblastoma Multiforme #RNAi Therapeutics

Silexion Therapeutics is a clinical-stage biopharmaceutical company developing RNA interference (RNAi)-based cancer therapies and delivery systems for malignant solid tumors, built on its proprietary LODER delivery platform. Lead programs include SIL204, an RNAi therapeutic targeting KRAS-driven cancers now in clinical development, and SiG12D-LODER, which completed an open-label Phase 1 trial in pancreatic cancer; Prostate-LODER and GBM-LODER are in preclinical development. The company collaborates with Evonik on advanced siRNA formulation and is headquartered in Jerusalem, Israel, with a Nasdaq listing since 2025.

Company Info

Sector:Biotechnology / Oncology (RNAi Therapeutics)

Headquarters:Jerusalem, Israel

Founded:2008

Website:silexion.com/

Upcoming Milestones & Key Dates

August 13, 2026

Financing

Expected closing of $2.5 million public offering

Clinical Development Pipeline

SIL204 (RNAi therapeutic)

Target: KRAS oncogene silencing via RNA interference

KRAS-driven cancers — clinical trial advancement

Preclinical

Phase 1

Phase 2

Phase 3

Approved

SiG12D-LODER

Target: siRNA targeting mutant KRAS (G12D) delivered via LODER implant

Pancreatic cancer

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Prostate-LODER / GBM-LODER

Target: LODER-delivered RNAi

Prostate cancer and glioblastoma multiforme

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Recent News

No recent news updates available for this company.

Leadership Team

Ilan Hadar

Chairman and Chief Executive Officer

Mirit Horenshtein Hadar

Executive Vice President of Finance Affairs, Chief Financial Officer and Secretary

Mitchell Shirvan

Chief Scientific and Development Officer

Careers & Job Openings

See all open roles

Multiple Departments

Jerusalem, Israel and remote

Apply Now →